ReviewAJR. American journal of roentgenology2024
Oral CT Contrast Agents: What's New and Why, From the
Review in AJR. American journal of roentgenology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety of positive gastrointestinal contrast media. Updated guidelines by the ESUR Contrast Media Safety Committee.European radiology · 2026Guideline
- An Alginate Hydrogel-Based Novel Oral Contrast Agent Designed for Gastric Computed Tomography Imaging.Chemical & biomedical imaging · 2026Article
- Reverse cupping-like appearance on CT: A beam hardening-related phenomenon with phantom correlation.Radiology case reports · 2026Article
- Prospective pilot evaluation of dark borosilicate oral contrast media for the evaluation of the stomach and small bowel using CT.Abdominal radiology (New York) · 2026Article
- Metal artifact reduction and contrast agent performance as a function of source spectral shape.Physics in medicine and biology · 2025Article
- Barium nanoparticles enhance efficacy of external beam radiation therapy in a preclinical basal-like mammary cancer mouse model.Scientific reports · 2025Article
- Insights into nanoparticle surface bonding and coating architecture via multinuclear NMR.Academia nano : science, materials, technology · 2025Article
- Use of oral contrast in 2024: primer for radiologists.Abdominal radiology (New York) · 2024Review
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
Current CT oral contrast agents improve the conspicuity of and confidence in bowel and peritoneal findings in many clinical scenarios, particularly for outpatient and oncologic abdominopelvic imaging. Yet, existing positive and neutral oral contrast agents may diminish the detectability of certain radiologic findings, frequently in the same scans in which the oral contrast agent improves the detectability of other findings. With ongoing improvements in CT technology, particularly multienergy CT, opportunities are opening for new types of oral contrast agents to further improve anatomic delineation and disease detection using CT. The CT signal of new dark oral contrast agents and of new high-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.